Stay updated with breaking news from Michael Detke. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Lighthouse Pharmaceuticals, a clinical-stage pharmaceutical company developing therapeutics to alter the course of Alzheimer's and other...
- Pre-IND meeting related to Phase 2b SPRING trial completed with US FDA - World-class clinical advisory board to support clinical development ...
Cortexyme has entered into a deal to acquire Novosteo. Once the deal is finalized, the two companies will enter the rare disease space and operate under the name Quince Therapeutics.
The 2022 International Conference on Alzheimer’s and Parkinson’s Disease ended last weekend, but it reported on numerous research studies and insights into the diseases.
(Reuters) - Cortexyme Inc said on Tuesday its experimental oral pill failed to meet the main goals of improving cognitive and functional abilities in ...